Antiglaucoma medications: A review of safety and tolerability issues related to their use

Joel S. Schuman

    Research output: Contribution to journalArticle

    Abstract

    Background: Much experience has been gained with the use of older classes of antiglaucoma agents-topical beta-adrenergic-receptor antagonists, nonselective adrenergic-receptor agonists, oral carbonic anhydrase inhibitors, and cholinergic agents. In the past decade, new drugs and classes of drugs used to treat glaucoma have become available, including topical carbonic anhydrase inhibitors, prostaglandin analogues, and alpha2- adrenergic-receptor agonists. Extensive community-based use of antiglaucoma medications has led to an increased understanding of the acute and long-term safety and tolerability issues associated with their use. Objective: This paper reviews the side effects associated with the various classes of topical antiglaucoma drugs, with a particular focus on long-term safety issues.

    Original languageEnglish (US)
    Pages (from-to)167-208
    Number of pages42
    JournalClinical Therapeutics
    Volume22
    Issue number2
    DOIs
    StatePublished - 2000

    Keywords

    • Adverse effects
    • Beta-adrenergic-receptor antagonists
    • Carbonic anhydrase inhibitors
    • Cholinergic agents
    • Glaucoma
    • Prostaglandin analogues

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Antiglaucoma medications: A review of safety and tolerability issues related to their use'. Together they form a unique fingerprint.

  • Cite this